Clinical trialsCompany release

EyePoint ends wet AMD programme after DURAVYU Phase 3 misses, cuts 53% of staff

🇺🇸 EyePoint, Inc. (EYPT) · Thu 12 Nov 2026

EyePoint will wind down wet AMD development of DURAVYU after LUGANO and LUCIA missed their primary endpoint, redirecting resources to its diabetic macular edema trials.

EyePoint, Inc. said in its third-quarter 2026 report, published on 12 November 2026, that the Phase 3 LUGANO and LUCIA trials of DURAVYU (vorolanib intravitreal insert) in wet age-related macular degeneration did not meet their primary endpoint. The endpoint was non-inferiority on best-corrected visual acuity (BCVA) against aflibercept.

The company will wind down the wet AMD programme and reduce its workforce by about 53%. EyePoint expects the restructuring to save roughly $30M a year.

Its priority now is diabetic macular edema (DME). The Phase 3 COMO and CAPRI trials are fully enrolled, and topline data are expected in early Q4 2027.

EyePoint reported $118M in cash as of 30 September 2026. The summary provided does not detail the trial results beyond the missed primary endpoint, nor the timing of the headcount reductions.

What it means for your team

  • Regulatory teams should note that a wet AMD filing for DURAVYU is no longer in prospect, as the company is winding down the indication.
  • Market-access and competitive-intelligence teams tracking the intravitreal space should shift DURAVYU monitoring to DME, where COMO and CAPRI topline data are due in early Q4 2027.
  • Failure against aflibercept on a non-inferiority BCVA endpoint illustrates how demanding the comparator bar remains in retinal disease trials.

Company's press release (SEC filing): EyePoint, Inc. ↗

Article written by VigiEye from the official source (EyePoint, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →